GlaxoSmithKline to pay Mass. over $35m
Accord part of $3b US fraud settlement
Pharmaceutical giant GlaxoSmithKline has agreed to pay more than $35 million to the Massachusetts Medicaid program as part of the British drug maker’s $3 billion settlement Monday with federal and state authorities in the largest US health care fraud case ever. The massive case centers around the promotion of prescription drugs for uses not approved by federal regulators, which is illegal. Although doctors may prescribe drugs for off-label treatments, companies can’t must limit their marketing to approved uses.